Stoke Therapeutics stock gains on Dravet data and Cantor conference plans

Stoke Therapeutics stock is trading near recent highs as investors weigh fresh long-term Dravet syndrome data and the company’s upcoming presentation at the Cantor Global Healthcare Conference.

Stoke Therapeutics stock (ISIN US86150R1023) is drawing attention after recent clinical data on its Dravet syndrome candidate zorevunersen and ahead of a scheduled presentation at the Cantor Global Healthcare Conference on September 9, 2026. According to market data compiled by MarketBeat, the shares recently opened at 30.89 US dollars, giving the company a market capitalization of about 1.99 billion US dollars as of September 2, 2026.

Clinical data underpin Dravet program

The current investor narrative around Stoke Therapeutics centers on zorevunersen, an investigational antisense RNA medicine for Dravet syndrome being developed together with Biogen. As summarized by Quiver Quantitative on September 2, 2026, Biogen and Stoke Therapeutics announced on September 1 that new presentations of long term zorevunersen data show durable seizure reduction alongside sustained improvements in cognition and behavior in treated patients, with a generally well tolerated safety profile over several years of follow up.

The same overview notes that enrollment in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome has reached its target, highlighting clear clinical momentum in the program as the companies prepare for longer term outcome readouts. For investors, the combination of durable seizure control and full Phase 3 enrollment is a key signal that the project has moved beyond early stage proof of concept and toward potential registration in a rare epilepsy indication where effective options remain limited.

Cantor conference appearance provides near term catalyst

In parallel with the data presentations, Stoke Therapeutics has flagged a capital markets event that may deliver additional detail on its pipeline and strategy. A short update carried by StockTitan and Yahoo Finance on September 2, 2026 reports that Stoke Therapeutics will present on September 9, 2026 at the Cantor Global Healthcare Conference, with corporate communications and investor relations contacts listed for further information. For retail investors, such conference slots often serve as platforms for management to provide updated timelines, discuss regulatory interactions and frame how new data could translate into future revenue streams.

Recent coverage by MarketBeat also points out that analysts currently maintain a Moderate Buy consensus on Stoke Therapeutics, with an average price target reported at 44.25 US dollars. Against the recent opening level of 30.89 US dollars, that implies upside potential of roughly 43 percent if the company executes on its clinical and business plans. At the same time, MarketBeat highlights that the company remains loss making, citing a recent quarterly loss of 0.93 US dollars per share, underlining the typical risk profile of clinical stage biotechnology names.

Pipeline products target genetic disease

Beyond Dravet syndrome, Stoke Therapeutics has built a broader pipeline of RNA based medicines designed to restore protein expression in genetic diseases. Yahoo Finance profiles the company’s lead assets, noting that STK 002 is in Phase 1 clinical trials for autosomal dominant optic atrophy, a hereditary eye disorder. In addition, zorevunersen, also known by the development code STK 001, is being evaluated in Phase 3 clinical trials in Dravet syndrome, reflecting the advanced status of that program.

The company’s approach focuses on using antisense oligonucleotides to upregulate or correct the expression of disease relevant proteins, a strategy that has already yielded approved therapies in other indications across the biotech sector. If long term data in Dravet and optic atrophy continue to show meaningful functional benefits with manageable safety, Stoke Therapeutics could eventually expand into additional genetic epilepsy or neurodevelopmental disorders, potentially broadening its addressable market beyond the initial rare disease targets.

Stock valuation and trading context

On the market side, MarketBeat data indicate that Stoke Therapeutics recently traded at 30.89 US dollars, with a reported price to earnings ratio of minus 9.25 given its current loss making status and a beta of 1.20. The negative earnings multiple simply reflects that the company has not yet reached profitability, while the beta figure signals a moderately higher volatility than the broader market, in line with many clinical stage biotech peers.

In terms of absolute size, the same MarketBeat snapshot shows a market capitalization of approximately 1.99 billion US dollars as of September 2, 2026. For context, the average price target of 44.25 US dollars cited by analysts sits well above the recent trading level, suggesting that the Street is willing to look through near term losses in anticipation of future revenue from successful zorevunersen and STK 002 launches. Compared with the current share price, that consensus target represents a potential gain of around 13.36 US dollars per share, again translating into more than 40 percent implied upside if forecasts materialize.

Representative product focus

A key representative product for Stoke Therapeutics at this stage is zorevunersen for Dravet syndrome. According to the Quiver Quantitative summary, the presentations on September 1, 2026 highlighted four year follow up data showing durable seizure reduction and maintained cognitive and behavioral improvements, alongside a favorable tolerability profile. For patients and families dealing with a severe childhood epilepsy that often proves resistant to existing medications, such durability is central to quality of life, and it directly supports the long term commercial narrative around the medicine.

Stock price as of early September 2026

Looking specifically at the share price, MarketBeat reports that Stoke Therapeutics stock opened at 30.89 US dollars on September 2, 2026 on the Nasdaq exchange. With a market capitalization of about 1.99 billion US dollars at that level, the company sits in the mid cap bracket within the United States biotech sector. The gap between this trading level and the 44.25 US dollar analyst consensus price target will likely remain sensitive to upcoming catalysts such as the Cantor Global Healthcare Conference presentation and further readouts from the EMPEROR Phase 3 study, as investors reassess probability of success and potential peak sales for zorevunersen.

Stoke Therapeutics at a glance

• Company: Stoke Therapeutics, Inc.
• ISIN: US86150R1023
• Ticker: STOK
• Trading venue: Nasdaq Global Select Market
• Price (as of September 2, 2026): 30.89 USD
• Market capitalization: 1.99 billion USD (as of September 2, 2026)
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: Nasdaq biotechnology segment